Redeye comments on Transtema’s Q3 report, showing 5.
Redeye provides an initial take on Kontigo Care’s Q3 2025 results.
Redeye provides its initial take on Acarix’s Q3 report, which showed record quarterly sales driven b...
Redeye updates on NextCell following its Q4 report, which showed figures largely aligning with estim...
Redeye updates on G5 Entertainment following Q3 results, which were softer than expected due to high...
Redeye provides an update following Neola Medical’s Q3 2025 report.
* An NDA for Orviglance submitted to the FDA * Patience for a partner deal * Fair value range update...
* Q3 soft, lower volumes from two major customers * We cut '26e-'27e sales and EBIT by 6% and SEK 6m...
* Pre-announced sales down 28% y-o-y due to several headwinds * 5m EE milestone pushed to '27 due to...
Redeye comments on the announcement that Moberg Pharma has signed an exclusive license agreement wit...
Redeye considers Bredband2’s Q3 report to be largely in line with estimates, posting growth of 9% y/...
* Q3 sales SEK 22m (-22% y-o-y), EBIT -6.4m (vs. ABGSCe -4.
Redeye provides an initial take on Cheffelo’s Q3 2025 report.
* Aims to grow DTC by ~30% CAGR next three years * We lower our '26e-'27e EBITA by 3-2% on cost ramp...
Redeye provides its first take on Oncopeptides' Q3 report 2025.
